4016 Stock Overview
Engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for 4016 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Middle East Pharmaceutical Industries Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س118.60 |
| 52 Week High | ر.س197.60 |
| 52 Week Low | ر.س90.20 |
| Beta | 0 |
| 1 Month Change | -3.42% |
| 3 Month Change | -9.05% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 11.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4016 | SA Pharmaceuticals | SA Market | |
|---|---|---|---|
| 7D | -2.3% | -0.8% | 0.3% |
| 1Y | n/a | 9.2% | -7.7% |
Return vs Industry: Insufficient data to determine how 4016 performed against the SA Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4016 performed against the SA Market.
Price Volatility
| 4016 volatility | |
|---|---|
| 4016 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in SA Market | 7.8% |
| 10% least volatile stocks in SA Market | 2.5% |
Stable Share Price: 4016 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4016's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 543 | Mohammed Maher Al-Ghannam | www.avalonpharmaceutical.com |
Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic medicines and preparations, including sexual system drugs, diabetes, cardiovascular drugs, anti-infective drugs, anti-parasitic drugs, pain relievers, antiseptics, and women’s and men’s health drugs in the form of creams, rolls, ointments, syrups, masks, tonics, lotions, capsules, gels, hand sanitizers, mouthwashes, soaps, solutions, sprays, scrubs, topical solutions, and tablets.
Middle East Pharmaceutical Industries Company Fundamentals Summary
| 4016 fundamental statistics | |
|---|---|
| Market cap | ر.س2.37b |
| Earnings (TTM) | ر.س80.44m |
| Revenue (TTM) | ر.س387.18m |
29.5x
P/E Ratio6.1x
P/S RatioIs 4016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4016 income statement (TTM) | |
|---|---|
| Revenue | ر.س387.18m |
| Cost of Revenue | ر.س143.25m |
| Gross Profit | ر.س243.93m |
| Other Expenses | ر.س163.49m |
| Earnings | ر.س80.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.02 |
| Gross Margin | 63.00% |
| Net Profit Margin | 20.78% |
| Debt/Equity Ratio | 22.6% |
How did 4016 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:16 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Middle East Pharmaceutical Industries Company is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Appissa | Al Rajhi Capital |
| null null | SNB Capital |